Cetuximab biosimilar - R-Pharm

Drug Profile

Cetuximab biosimilar - R-Pharm

Alternative Names: Erbitux biosimilar - R-Pharm; RPH 002

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator R-Pharm
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 04 Sep 2017 Cetuximab biosimilar is still in clinical trials for Head and neck cancer (R-Pharm pipeline, August 2017)
  • 15 May 2015 R-Pharm announces intention to submit MAA in Russia and Turkey in 2015
  • 11 May 2015 Phase III clinical trials in Head and neck cancer (Metastatic disease, Recurrent, Treatment-resistant) in Turkey (IV) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top